New

Global ETF Survey 2026: Answer now →

Help us improve your experience. Please confirm your investor type:

Compare ETFs Easily

The Ultimate ETF Comparison Tool - Try Now!

Analyze up to 5 ETFs side-by-side and gain instant insights on performance, fees, holdings, and more to make data-driven investment decisions.

›ETF Issuers›Ark Investment›ARKG
ETF screener

ARKG ETF · ARK Genomic Revolution ETF

The ARKG Exchange Traded Fund (ETF) is provided by Ark Investment. This fund is actively managed; it does not track an index. This share class generates a stream of income by distributing dividends.
Last update 7/2/2026, 1:30 PM UTC
LIVE
CLOSED
This fund is part ofBioTech & Genomics1M perf.+24.39%
Last price
$42.91
1M perf.
+26.19%
1M flows
+€54M
AuM
€1.48B
TER
0.75%
Rating
Not rated
ARKG
$42.91

Performance & flows

Segment for quartile rank
April 2, 2026 → July 2, 2026
00%10%20%30%40%50%60%MAYJUNJULMAYJUNJUL
Create a free account to view the flows graph
ARKG
$42.97
+56.95%
BioTech & Genomics
+46.29%

Historic performance and flows

1M3M1Y3Y5YMTDQTDYTD
Perf.
+26.19%
icon
+56.95%
icon
+70.70%
icon
+26.78%
icon
-52.97%
icon
+2.07%
+2.07%
+47.14%
icon
Flows

Key fund info

Segment for quartile rank
This ETF's jurisdiction country is not in your region (Europe and Middle East) Â· 
Main characteristics
CUSIP
00214Q302
ISIN
US00214Q3020
AuM
€1.48B
icon
TER
0.75%
icon
More details
NAV
7/2/2026
$42.96
1D NAV change
+0.66%
Dividend policy
No. of holdings
N/A
Inception date
4/2/2019
Jurisdiction
United States
Distribution
United States
Legal structure
Open-end Management Investment Company
Base currency
USD
Dividend distribution
Trailing 12-month distr. yield
Distribution frequency
Last distribution
Create a free account to view dividend distribution
Classification
Product type
Asset class
Factors
N/A
Investment strategy
ARKG is an actively managed ETF that seeks long-term growth of capital by investing under normal circumstances primarily (at least 80% of its assets) in domestic and foreign equity securities of companies across multiple sectors, including health care, information technology, materials, energy and consumer discretionary, that are relevant to the Fund’s investment theme of the genomics revolution.
Tax optimisation
PEA
France
UK Reporting Status
United Kingdom
Create a free Trackinsight Essentials account to unlock insights
Access exclusive metrics and features to support your investment decisions.
half moonhalf moon double
New to Trackinsight?
For individual investors

Trackinsight
Essentials

A forever free toolbox for fund selection, analysis, research, and ETF portfolio construction.
More fund data
Compare up to 3 funds
More screener filters
Choose your own screener columns from 100+ metrics
Lists for saving your research
Portfolio construction and analysis
Personal dashboard for live monitoring
For professional investors

Trackinsight
Enterprise

Trackinsight Enterprise addresses the everyday operational, regulatory, and analytical pain points faced by professional and institutional ETF investors, from selection to execution.
Request a free trial
More professional services:ETF Data ServicesDue Diligence Services

Advertisement

Risk profile

Segment for quartile rank

Historical risk/return profile

3M1Y3Y5Y
Returns
+56.95%
icon
+70.70%
icon
+26.78%
icon
-52.97%
icon
Volatility
Perf./Volatility
Max drawdown
Create a free account to view risk/return table
Synthetic Risk and Reward Indicator (SRRI)
UCITS
N/A
PRIIPS
N/A
More exposure metrics are available, exclusively in Trackinsight Enterprise

Exposure

Countries
Unavailable
100.00%
Sectors
Unavailable
100.00%
Diversification
This fund does not provide direct exposure to underlying securities.
Top 15 holdings
0
This fund does not provide direct exposure to underlying securities
More risk metrics are available, exclusively in Trackinsight Enterprise

Sustainability

Integrates ESG criteria
No
SDG
More sustainability metrics are available, exclusively in Trackinsight Enterprise

Issuer

Ark Investment
Ark Investment ID Card
Number of funds
11
Total AuM
€12.32B
Expense ratio range
0.49% - 1.44%
Average expense ratio
0.8082%
Top 5 funds by Ark Investment
AuM
ARKK
ARK Innovation ETF€5.86B
ARKQ
ARK Autonomous Technology & Robotics ETF€1.86B
ARKG
ARK Genomic Revolution ETF€1.48B
ARKW
ARK Next Generation Internet ETF€1.47B
ARKX
ARK Space & Defense Innovation ETF€812M

Frequently asked questions about ARKG

What does ARK Genomic Revolution ETF, ARKG, invest in?

ARKG is a Active ETF. This ETF provides exposure to Other Equities.

What is the Total Expense ratio (TER) of ARKG?

ARKG carries a total expense ratio (TER) of 0.75%, indicating the annual cost for holding the fund.

When was ARKG launched?

ARKG was introduced to the market on April 2, 2019. It trades on United States

Who is the ETF issuer of ARKG?

ARK Genomic Revolution ETF, ARKG, is provided by Ark Investment. Learn more about Ark Investment here.

What is the current assets under management (AUM) of ARKG?

ARKG oversees €1.48B in assets as of July 2, 2026.

How has ARKG performed lately?

Based on data from July 2, 2026, ARKG returned 26.19% over the past month, 56.95% over the last three months and 47.14% year-to-date.

What are the latest inflows or outflows for ARKG?

As of July 2, 2026, ARKG recorded net flows of +€55M over the last month and -€9.8M year-to-date.

Does ARKG distribute dividends?

ARKG follows a distributing dividend policy, meaning it pays out income to investors.

What is the base currency of ARKG?

The base currency of ARKG is USD.

Advertisement

Trackinsight

About Trackinsight

Since our founding in 2016, we have been at the forefront of the industry, delivering accessible, comprehensive, and reliable tools to support the evolving needs of investors.

Over the past decade, Trackinsight has expanded its operations across six countries, serving thousands of professional investors. We’ve consistently innovated to provide cutting-edge solutions that meet the changing demands of the ETF market.

In 2024, Kepler Cheuvreux, a leading independent European financial services firm, acquired a majority stake in Trackinsight, becoming the company's principal shareholder.

This strategic partnership solidifies Trackinsight's position as a premier provider of ETF selection and analysis tools, while strengthening Kepler Cheuvreux’s commitment to becoming a leading player in the ETF sector.

Together, we are committed to offering advanced services that empower professional investors, advisors, institutions, and issuers. This new step enables us to deliver even more comprehensive and innovative technological solutions, driving ETF investing to new heights.

More about Trackinsight
© 2014-2026 Trackinsight SA. All rights reserved.
Privacy policy  |  Cookie policy  |    |  Terms of use  |  Imprint
Trackinsight